Long-term neuropsychologic outcome of pre-emptive mTOR inhibitor treatment in children with tuberous sclerosis complex (TSC) under 4 months of age (PROTECT), a two-arm, randomized, observer-blind, controlled phase IIb national multicentre clinical trial: study protocol
Abstract Background Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder affecting multiple organ systems, with a prevalence of 1:6,760–1:13,520 live births in Germany. On the molecular level, TSC is caused by heterozygous loss-of-function variants in either of the genes TSC1 o...
Saved in:
Main Authors: | Jan H. Driedger, Julian Schröter, PROTECT-Study Group, Steffen Syrbe, Afshin Saffari |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2025-01-01
|
Series: | Orphanet Journal of Rare Diseases |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13023-024-03495-1 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Molecular mechanisms of mTOR-mediated cisplatin response in tumor cells
by: Amirhosein Maharati, et al.
Published: (2025-01-01) -
KaRhab: an international online registry for cardiac rhabdomyomas
by: Vera-Maria Herrmann, et al.
Published: (2025-01-01) -
AKT/mTOR信号通路在喉癌组织中的表达及意义
Published: (2009-01-01) -
Reactivation of mTOR signaling slows neurodegeneration in a lysosomal sphingolipid storage disease
by: Hongling Zhu, et al.
Published: (2025-01-01) -
Porphyra haitanensis polysaccharide (PH) attenuates cell hyperplasia via remodeling the cross-talk between Hippo/YAP and mTOR pathways
by: Chong Wang, et al.
Published: (2023-03-01)